Reductions in liver enzymes are associated with anti-hyperglycaemic and anti-obesity effects of tofogliflozin in people with type 2 diabetes: Post-hoc analyses.

Toshinari Takamura Kohei KakuAkihiro YoshidaHiromi KusakabeHiroyuki NakamuraHideki Suganami

Published in: Endocrinology, diabetes & metabolism (2023)

Reductions in GGT and ALT were associated with the anti-hyperglycaemic and anti-obesity effects of tofogliflozin, respectively, in people with T2D. Therefore, GGT and ALT may be surrogate markers for hyperglycaemia and obesity in T2D.

Keyphrases

insulin resistance
metabolic syndrome
weight loss
type diabetes
high fat diet induced
weight gain
adipose tissue
skeletal muscle